NCT03326986View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 10, 2017

Primary Completion Date

December 17, 2018

Study Completion Date

December 17, 2018

Conditions
PharmacokineticsCancer
Interventions
DRUG

MK-7252

1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL

DRUG

Placebo

Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL

Trial Locations (1)

9000

Universitair Ziekenhuis Gent ( Site 0001), Ghent

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03326986 - Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001) | Biotech Hunter | Biotech Hunter